CXCR1 and neoplasm: Recent studies demonstrate that SX-682, an oral CXCR1/2 inhibitor, disrupts MDSC trafficking, and improves tumor control by anti-PD1 therapy in an oral cancer model [174], as previously shown in other tumor models [175, 176].